Theravance Biopharma (TBPH) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Theravance Biopharma is set to report its Q2 2025 earnings on August 4th, with analysts predicting a loss of ($0.12) per share and revenues of $16.04 million.
• In its last earnings report, the company reported a loss of ($0.27) per share, significantly missing expectations, and generated revenue of $15.39 million.
• Analysts currently have a mixed outlook on the stock, with an average target price of $16.60 and ratings ranging from "hold" to "strong buy."

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) is expected to be posting its Q2 2025 quarterly earnings results after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $16.04 million for the quarter.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The business had revenue of $15.39 million during the quarter, compared to analyst estimates of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. On average, analysts expect Theravance Biopharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Theravance Biopharma Stock Down 0.2%

Shares of NASDAQ:TBPH traded down $0.02 during trading on Thursday, reaching $11.05. 61,095 shares of the company traded hands, compared to its average volume of 246,543. The firm has a market capitalization of $552.46 million, a PE ratio of -9.35 and a beta of -0.02. The company's 50 day moving average is $10.80 and its two-hundred day moving average is $9.78. Theravance Biopharma has a 52 week low of $7.44 and a 52 week high of $11.88.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TBPH. Jones Trading upgraded Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target for the company in a report on Tuesday, June 17th. BTIG Research upped their price target on shares of Theravance Biopharma from $24.00 to $25.00 and gave the company a "buy" rating in a research note on Friday, June 27th. Finally, Wall Street Zen lowered Theravance Biopharma from a "buy" rating to a "hold" rating in a report on Saturday, July 12th. Four research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Theravance Biopharma has an average rating of "Moderate Buy" and an average price target of $16.60.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total transaction of $264,000.00. Following the completion of the transaction, the senior vice president directly owned 336,918 shares of the company's stock, valued at approximately $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 44,000 shares of company stock valued at $491,800 in the last quarter. 6.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Theravance Biopharma stock. Jane Street Group LLC grew its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 169.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,884 shares of the biopharmaceutical company's stock after acquiring an additional 88,540 shares during the period. Jane Street Group LLC owned 0.28% of Theravance Biopharma worth $1,258,000 at the end of the most recent reporting period. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.